폐 약물전달 디바이스 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Pulmonary Drug Delivery Devices Market - Scope of Report

TMR's report on the global pulmonary drug delivery devices market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global pulmonary drug delivery devices market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pulmonary drug delivery devices market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pulmonary drug delivery devices market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pulmonary drug delivery devices market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pulmonary drug delivery devices market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pulmonary drug delivery devices market.

The report delves into the competitive landscape of the global pulmonary drug delivery devices market. Key players operating in the global pulmonary drug delivery devices market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pulmonary drug delivery devices market profiled in this report.

Key Questions Answered in Global pulmonary drug delivery devices Market Report:

• What is the sales/revenue generated by pulmonary drug delivery devices across all regions during the forecast period?
• What are the opportunities in the global pulmonary drug delivery devices market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Pulmonary Drug Delivery Devices Market - Research Objectives and Research Approach

The comprehensive report on the global pulmonary drug delivery devices market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global pulmonary drug delivery devices market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pulmonary drug delivery devices market.

Table of Contents

1. Executive Summary

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pulmonary Drug Delivery Devices Market

4. Market Overview

• 4.1. Market Segmentation
  • 4.1.1. Segment Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, 2023-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
• 5.3. COVID-19 Pandemic Impact on Industry

6. Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Product Type

• 6.1. Introduction and Definitions
• 6.2. Key Findings/Developments
• 6.3. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 6.3.1. Dry Powder Inhalers
  • 6.3.2. Metered Dose Inhalers
  • 6.3.3. Nebulizers
• 6.4. Market Attractiveness, by Product Type

7. Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Application

• 7.1. Introduction and Definitions
• 7.2. Key Findings/Developments
• 7.3. Market Value & Volume Forecast, by Application, 2023-2031
  • 7.3.1. Asthma
  • 7.3.2. COPD
  • 7.3.3. Cystic Fibrosis
  • 7.3.4. Others
• 7.4. Market Attractiveness, by Application

8. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Distribution Channel

• 8.1. Introduction and Definitions
• 8.2. Key Findings/Developments
• 8.3. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 8.3.1. Retail Pharmacies
  • 8.3.2. Hospital Pharmacies
  • 8.3.3. E-Commerce
• 8.4. Market Attractiveness, by Distribution Channel

9. Global Pulmonary Drug Delivery Devices Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value & Volume Forecast, by Region, 2023-2031
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness, by Region

10. North America Pulmonary Drug Delivery Devices Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 10.2.1. Dry Powder Inhalers
  • 10.2.2. Metered Dose Inhalers
  • 10.2.3. Nebulizers
• 10.3. Market Attractiveness, by Product Type
• 10.4. Market Value & Volume Forecast, by Application, 2023-2031
  • 10.4.1. Asthma
  • 10.4.2. COPD
  • 10.4.3. Cystic Fibrosis
  • 10.4.4. Others
• 10.5. Market Attractiveness, by Application
• 10.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 10.6.1. Retail Pharmacies
  • 10.6.2. Hospital Pharmacies
  • 10.6.3. E-Commerce
• 10.7. Market Attractiveness, by Distribution Channel
• 10.8. Market Value & Volume Forecast, by Country, 2023-2031
  • 10.8.1. U.S.
  • 10.8.2. Canada
• 10.9. Market Attractiveness Analysis
  • 10.9.1. By Product Type
  • 10.9.2. By Application
  • 10.9.3. By Distribution Channel
  • 10.9.4. By Country

11. Europe Pulmonary Drug Delivery Devices Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 11.2.1. Dry Powder Inhalers
  • 11.2.2. Metered Dose Inhalers
  • 11.2.3. Nebulizers
• 11.3. Market Attractiveness, by Product Type
• 11.4. Market Value & Volume Forecast, by Application, 2023-2031
  • 11.4.1. Asthma
  • 11.4.2. COPD
  • 11.4.3. Cystic Fibrosis
  • 11.4.4. Others
• 11.5. Market Attractiveness, by Application
• 11.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 11.6.1. Retail Pharmacies
  • 11.6.2. Hospital Pharmacies
  • 11.6.3. E-Commerce
• 11.7. Market Attractiveness, by Distribution Channel
• 11.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
  • 11.8.1. Germany
  • 11.8.2. U.K.
  • 11.8.3. France
  • 11.8.4. Italy
  • 11.8.5. Spain
  • 11.8.6. Rest of Europe
• 11.9. Market Attractiveness Analysis
  • 11.9.1. By Product Type
  • 11.9.2. By Application
  • 11.9.3. By Distribution Channel
  • 11.9.4. By Country/Sub-region

12. Asia Pacific Pulmonary Drug Delivery Devices Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 12.2.1. Dry Powder Inhalers
  • 12.2.2. Metered Dose Inhalers
  • 12.2.3. Nebulizers
• 12.3. Market Attractiveness, by Product Type
• 12.4. Market Value & Volume Forecast, by Application, 2023-2031
  • 12.4.1. Asthma
  • 12.4.2. COPD
  • 12.4.3. Cystic Fibrosis
  • 12.4.4. Others
• 12.5. Market Attractiveness, by Application
• 12.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 12.6.1. Retail Pharmacies
  • 12.6.2. Hospital Pharmacies
  • 12.6.3. E-Commerce
• 12.7. Market Attractiveness, by Distribution Channel
• 12.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
  • 12.8.1. China
  • 12.8.2. Japan
  • 12.8.3. India
  • 12.8.4. Australia & New Zealand
  • 12.8.5. Rest of Asia Pacific
• 12.9. Market Attractiveness Analysis
  • 12.9.1. By Product Type
  • 12.9.2. By Application
  • 12.9.3. By Distribution Channel
  • 12.9.4. By Country/Sub-region

13. Latin America Pulmonary Drug Delivery Devices Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 13.2.1. Dry Powder Inhalers
  • 13.2.2. Metered Dose Inhalers
  • 13.2.3. Nebulizers
• 13.3. Market Attractiveness, by Product Type
• 13.4. Market Value & Volume Forecast, by Application, 2023-2031
  • 13.4.1. Asthma
  • 13.4.2. COPD
  • 13.4.3. Cystic Fibrosis
  • 13.4.4. Others
• 13.5. Market Attractiveness, by Application
• 13.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 13.6.1. Retail Pharmacies
  • 13.6.2. Hospital Pharmacies
  • 13.6.3. E-Commerce
• 13.7. Market Attractiveness, by Distribution Channel
• 13.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
  • 13.8.1. Brazil
  • 13.8.2. Mexico
  • 13.8.3. Rest of Latin America
• 13.9. Market Attractiveness Analysis
  • 13.9.1. By Product Type
  • 13.9.2. By Application
  • 13.9.3. By Distribution Channel
  • 13.9.4. By Country/Sub-region

14. Middle East & Africa Pulmonary Drug Delivery Devices Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value & Volume Forecast, by Product Type, 2023-2031
  • 14.2.1. Dry Powder Inhalers
  • 14.2.2. Metered Dose Inhalers
  • 14.2.3. Nebulizers
• 14.3. Market Attractiveness, by Product Type
• 14.4. Market Value & Volume Forecast, by Application, 2023-2031
  • 14.4.1. Asthma
  • 14.4.2. COPD
  • 14.4.3. Cystic Fibrosis
  • 14.4.4. Others
• 14.5. Market Attractiveness, by Application
• 14.6. Market Value & Volume Forecast, by Distribution Channel, 2023-2031
  • 14.6.1. Retail Pharmacies
  • 14.6.2. Hospital Pharmacies
  • 14.6.3. E-Commerce
• 14.7. Market Attractiveness, by Distribution Channel
• 14.8. Market Value & Volume Forecast, by Country/Sub-region, 2023-2031
  • 14.8.1. GCC Countries
  • 14.8.2. South Africa
  • 14.8.3. Rest of Middle East & Africa
• 14.9. Market Attractiveness Analysis
  • 14.9.1. By Product Type
  • 14.9.2. By Application
  • 14.9.3. By Distribution Channel
  • 14.9.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2022)
• 15.3. Company Profiles
  • 15.3.1. AstraZeneca Plc
    • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.1.2. Product Type Portfolio
    • 15.3.1.3. Financial Overview
    • 15.3.1.4. SWOT Analysis
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Novartis AG
    • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.2.2. Product Type Portfolio
    • 15.3.2.3. Financial Overview
    • 15.3.2.4. SWOT Analysis
    • 15.3.2.5. Strategic Overview
  • 15.3.3. Boehringer Ingelheim GmbH
    • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.3.2. Product Type Portfolio
    • 15.3.3.3. Financial Overview
    • 15.3.3.4. SWOT Analysis
    • 15.3.3.5. Strategic Overview
  • 15.3.4. GlaxoSmithKline Plc
    • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.4.2. Product Type Portfolio
    • 15.3.4.3. Financial Overview
    • 15.3.4.4. SWOT Analysis
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Merck & Co., Inc.
    • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.5.2. Product Type Portfolio
    • 15.3.5.3. Financial Overview
    • 15.3.5.4. SWOT Analysis
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Teva Pharmaceutical Industries Ltd.
    • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.6.2. Product Type Portfolio
    • 15.3.6.3. Financial Overview
    • 15.3.6.4. SWOT Analysis
    • 15.3.6.5. Strategic Overview